Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Profiling of the immune microenvironment in FL [PanCancer Immune Profiling]

ABSTRACT: Profiling of the immune microenvironment in FL [PanCancer Immune Profiling]

PROVIDER: PRJNA613070 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Profiling of the immune microenvironment in FL [PanCancer Immune Profiling]

Project description:Tumor cells orchestrate their microenvironment. Here, we provide biochemical, structural, functional and clinical evidence that Cathepsin S (CTSS) alterations induce a tumor-promoting immune microenvironment in follicular lymphoma (FL). We found CTSS mutations at Y132 in 6% of FL (19/305). Another 13% (37/286) had CTSS amplification, which was associated with higher CTSS expression. CTSS Y132 mutations lead to accelerated autocatalytic conversion from pro-CTSS to active CTSS and increase substrate cleavage, including CD74 which regulates MHC-II-restricted antigen presentation. Lymphoma cells with hyperactive CTSS more efficiently activated antigen-specific CD4+ T-cells in vitro. Tumors with hyperactive CTSS showed increased CD4+ T-cell infiltration and proinflammatory cytokine perturbation in a mouse model and in human FLs. In mice, this CTSS-induced immune microenvironment promoted tumor growth. Clinically, patients with CTSS-hyperactive FL had better treatment outcomes with standard immunochemotherapies, indicating that these immunosuppressive regimens target both the lymphoma cells and the tumor-promoting immune microenvironment. Digital multiplexed gene expression profiling of formalin-fixed and paraffin-embedded biopsy specimens of the GLSG2000 cohort was performed as previously described (Hellmuth et al., Blood 2018)

2020-03-18 | GSE147125 | GEO

Profiling of the immune microenvironment in FL

Project description:Profiling of the immune microenvironment in FL

| PRJNA612827 | ENA

Profiling of the immune microenvironment in FL

Project description:Tumor cells orchestrate their microenvironment. Here, we provide biochemical, structural, functional and clinical evidence that Cathepsin S (CTSS) alterations induce a tumor-promoting immune microenvironment in follicular lymphoma (FL). We found CTSS mutations at Y132 in 6% of FL (19/305). Another 13% (37/286) had CTSS amplification, which was associated with higher CTSS expression. CTSS Y132 mutations lead to accelerated autocatalytic conversion from pro-CTSS to active CTSS and increase substrate cleavage, including CD74 which regulates MHC-II-restricted antigen presentation. Lymphoma cells with hyperactive CTSS more efficiently activated antigen-specific CD4+ T-cells in vitro. Tumors with hyperactive CTSS showed increased CD4+ T-cell infiltration and proinflammatory cytokine perturbation in a mouse model and in human FLs. In mice, this CTSS-induced immune microenvironment promoted tumor growth. Clinically, patients with CTSS-hyperactive FL had better treatment outcomes with standard immunochemotherapies, indicating that these immunosuppressive regimens target both the lymphoma cells and the tumor-promoting immune microenvironment. Digital multiplexed gene expression profiling of formalin-fixed and paraffin-embedded biopsy specimens of the validation cohort was performed as previously described (Hellmuth et al., Blood 2018)

2020-03-17 | GSE147033 | GEO

PanCancer Immune panel on treated tumors

Project description:Our data showed that ENT broadly impacted multiple populations of immune cells within the TME. Thus, we performed general immune transcriptome profiling on whole tumors isolated from the neu-N model using a PanCancer immune-profiling gene panel for the NanoString platform.

2018-10-10 | GSE121031 | GEO

PanCancer Immune panel on treated tumors

Project description:PanCancer Immune panel on treated tumors

| PRJNA495381 | ENA

NanoString PanCancer Immune Profiling of 4′‐bromo‐resveratrol treated BrafV600E/PtenNULL melanoma mice

Project description:We performed differential gene expression analysis using high throughput multiplex analysis via NanoString nCounter PanCancer Immune Profiling panel, which analyzes 770 genes related to cancer-immune pathways (cancer progression, chemokines and cytokines and their receptors, and innate and adaptive immune response). nSolver software was used to analyze the data and a heat map was generated to show differential expression of 770 genes. Further, using a fold cut-off of ≥2 and p-value <0.05, we observed that 4'-BR significantly modulated expression of multiple cancer immune genes.

2021-11-29 | GSE168564 | GEO

Transcriptomic analysis of orthotopic pancreatic tumors treated by Axl inhibitor TP-0903 or combination with chemo/immunotherapy using the nCounter PanCancer Immune Profiling panel (Nanostring Technologies) [mouse]

Project description:RNA isolated from KPfC orthotopic tumors was analyzed using Mouse PanCancer Immune Profiling Panel (NanoString Technologies).

2021-11-01 | GSE185110 | GEO

Tracking immune cells from brain metastasis microenvironment to the cerebrospinal fluid

Project description:PanCancer Immune Panel profiling of 50 brain metastases

2020-10-13 | GSE159407 | GEO

Transcriptomic analsyis of Epithelial and Mesenchymal carcinoma cells using the nCounter PanCancer Immune Profiling panel (Nanostring Technologies) [mouse]

Project description:We undertook to determine whether carcinoma cells residing in the epithelial or quasi-mesenchymal phenotypic states differ in their expression of immunomodulatory markers. To do so, we used the nCounter PanCancer Immune Profiling Panel (Nanostring Technologies)to perform transcriptomic analyses of the E and qM mammary carcinoma cells; these cells were either cultured in vitro or prepared by FACS sorting of GFP-labelled carcinoma cells from their corresponding tumors

2021-09-15 | GSE161746 | GEO

NanoString PanCancer Immune Profiling of 4′‐bromo‐resveratrol treated BrafV600E/PtenNULL melanoma mice

Project description:NanoString PanCancer Immune Profiling of 4′‐bromo‐resveratrol treated BrafV600E/PtenNULL melanoma mice

| PRJNA708302 | ENA